期刊
CURRENT OPINION IN INFECTIOUS DISEASES
卷 31, 期 4, 页码 309-315出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QCO.0000000000000461
关键词
allograft rejection; humoral immunity; immunogenicity; seroconversion; seroprotection
资金
- Swiss National Science Foundation [P2BEP3_175265]
- Swiss National Science Foundation (SNF) [P2BEP3_175265] Funding Source: Swiss National Science Foundation (SNF)
Purpose of review The aim of this study was to highlight recent evidence on important aspects of influenza vaccination in solid organ transplant recipients. Recent findings Influenza vaccine is the most evaluated vaccine in transplant recipients. The immunogenicity of the vaccine is suboptimal after transplantation. Newer formulations such as inactivated unadjuvanted high-dose influenza vaccine and the administration of a booster dose within the same season have shown to increase response rates. Intradermal vaccination and adjuvanted vaccines did not show clear benefit over standard influenza vaccines. Recent studies in transplant recipients do not suggest a higher risk for allograft rejection, neither after vaccination with a standard influenza vaccine nor after the administration of nonstandard formulation (high-dose, adjuvanted vaccines), routes (intradermally) or a booster dose. Nevertheless, influenza vaccine coverage in transplant recipients is still unsatisfactory low, potentially due to misinterpretation of risks and benefits. Summary Annual influenza vaccination is well tolerated and is an important part of long-term care of solid organ transplant recipients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据